Lipoprotein lipase activity and common gene variants in severely hypertriglyceridemic patients with and without diabetes

Hormone Research

Volumn 60, Issue 2, 2003, Pages 61-67

  Chadarevian, Rita ^a   Foubert, Luc ^a   Beucler, Isabel ^b   Kottler, Marie Laure ^b   Raisonnier, Alain ^b   Ajlouni, Ali ^b   Giral, Philippe ^a   Turpin, Gérard ^a   Bruckert, Eric ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Apolipoprotein E; Diabetes mellitus; Lipoprotein lipase activity; Lipoprotein lipase gene variants; Triglyceride; Type IV hypertriglyceridemia

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A; ASPARAGINE; ASPARTIC ACID; CHOLESTEROL; GLUTAMIC ACID; GLYCINE; HEPARIN; LIPOPROTEIN LIPASE; SERINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYMOLOGY; EXON; FEMALE; GENE LOCATION; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENETICS; HETEROZYGOSITY; HOSPITALIZATION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 4; HYPERTRIGLYCERIDEMIA; MALE; OUTCOMES RESEARCH; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEINS; ASPARAGINE; ASPARTIC ACID; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GLUTAMIC ACID; GLYCINE; HUMANS; HYPERLIPOPROTEINEMIA TYPE IV; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; PHENOTYPE; SERINE; SEVERITY OF ILLNESS INDEX; VARIATION (GENETICS);

EID: 0041742326     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071872     Document Type: Article

References (36)

1. Baron TH, Morgan DE: Acute necrotizing pancreatitis. N Engl J Med 1999;340:1412-1417.
2. Nikkila EA: Familial lipoprotein lipase deficiencies and related disorders of chylomicron metabolism; in Stanbury JB, Wyngaarder JB, Fredrickson DS, Goldstein JL, Brown MS (eds): The Metabolic Basis of Inherited Disease, ed 5. New York, McGraw-Hill, 1983, pp 622-642.
3. Chait A, Brunzell JD: Severe hypertriglyceridemia: Role of familial and acquired disorders. Metabolism 1983;32:209-213.
4. Assmann G, Gotto AM, Paoletti R: The hypertriglyceridemias: Risk and management. Am J Cardiol 1991;68:1A-42A.
5. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G: Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158-166.
6. Sniderman AD, Zhang Z, Cianflone K: Divergent responses of the liver to increased delivery of glucose or fatty acids: Implications for the pathogenesis of type IV hyperlipoproteinemia. Atherosclerosis 1998;137:291-301.
7. McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G: Carbohydrate induced hypertriglyceridemia: An insight into the link between plasma insulin and triglyceride concentrations. J Clin Endocrinol Metab 2000;85:3085-3088.
8. Tsutsumi Z, Ikeda Y, Tsushima M, Higashino K, Yamamoto A: Alcohol-induced hypertri glyceridemia in subjects with decreased lipoprotein lipase-improvement after cessation of alcohol intake. Nippon Shokakibyo Gakkai Zasshi 1995;92:951-959.
9. Kreisberg RA: Diabetic dyslipidemia. Am J Cardiol 1998;82:67-73.
10. Taskinen MR: Lipoprotein lipase in diabetes. Diabetes Metab Rev 1987;3:551-570.
11. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR: Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997;40:454-462.
12. Ginsberg HN: Lipoprotein physiology in non-diabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 1991;14:839-855.
13. Gotto AM Jr: Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998;82:22-25.
14. Kastelein JJ, Groenemeyer BE, Hallman DM, Henderson H, Reyme PW, Gagne SE, Jansen H, Seidell JC, Kromhout D, Jukema JW, Bruschke AV, Boerwinkle E, Hayden MR: The Asn-9 variant of lipoprotein lipase is associated with the 93G promoter mutation and an increased risk of coronary artery disease. The Regress Study. Clin Genet 1998;53:27-33.
15. Mailly F, Tugrul Y, Reymer PW, Bruin T, Seed M, Groenemeyer BF, Asplund-Carlson A, Vallance D, Winder AF, Miller CJ: A common variant in the gene for lipoprotein lipase (Asp 9 Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1995;4:468-478.
16. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjærg-Hansen A: Heterozygous lipoprotein lipase deficiency: Frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997;96:1737-1744.
17. Miesenbock G, Holzl B, Foger B, Brandstatter E, Paulweber B, Sandhofer F, Patsch JR: Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J Clin Invest 1993;91:448-455.
18. Kastelein JJ, Ordovas JM, Wittekoek ME, Pimstone SN, Wilson W, Gagne SE, Larson MG, Schaefer EJ, Boer JM, Gerdes C, Hayden MR: Two common mutations (D9N, N291S) in lipoprotein lipase: A cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clin Genet 1999;56:297-305.
19. Knudsen P, Murtomaki S, Antikainen M, Ehnholm S, Lahdenpera S, Ehnholm C, Taskinen MR: The Asn-291→Ser and Ser-447→stop mutations of the lipoprotein lipase gene and their significance for lipid metabolism in patients with hypertriglyceridemia. Eur J Clin Invest 1997;27:928-935.
20. Pimstone SN, Clee SM, Gagne SE, Miao L, Zhang H, Stein EA, Hayden MR: A frequently occurring mutation in the lipoprotein lipase gene (Asn 291 Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. J Lipid Res 1996;37:1675-1684.
21. Hoffer MJ, Bredie SJ, Boomsma DI, Reymer PW, Kastelein JJ, de Knijff P, Demacker PN, Stalenhoef AF, Havekes LM, Frants RR: The lipoprotein lipase (Asn 291→Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. Atherosclerosis 1996;119:159-167.
22. Minnich A, Kessling A, Roy M, Giry C, DeLangavant G, Lavigne J, Lussier-Cacan S, Davignon J: Prevalence of alleles encoding defective lipoprotein lipase in hypertriglyceridemic patients of French-Canadian descent. J Lipid Res 1995;36:117-124.
23. Groenemeyer BE, Hallman MD, Reymer PW, Gagne E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ: Genetic variant showing a positive interaction with β-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser 447→stop substitution in the lipoprotein lipase gene. Regress Study Group. Circulation 1997;95:2628-2635.
24. Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ: Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: The European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vasc Biol 1998;18:526-534.
25. Gagne SE, Larson MG, Pimstone SN, Schaefer EJ, Kastelein JJ, Wilson PW, Ordovas JM, Hayden MR: A common truncation of lipoprotein lipase (Ser 447 X) confers protection against coronary heart disease. The Framingham Offspring Study. Clin Genet 1999;55:450-454.
26. Wittrup HH, Tybjærg-Hansen A, Nordestgaard BG: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901-2907.
27. Saidi Y, Sich D, Camproux A, Egloff M, Federspiel MC, Gautier V, Raisonnier A, Turpin G, Beucler I: Interrelationships between postprandial lipoprotein B: CIII particle changes and high-density lipoprotein subpopulation profiles in mixed hyperlipoproteinemia. Metabolism 1999;48:60-67.
28. Zsigmond E, Fuke Y, Li L, Kobayashi K, Chan L: Resistance of chylomicron and VLDL remnants to post-heparin lipolysis in ApoE-deficient mice: The role of ApoE in lipoprotein lipase-mediated lipolysis in vivo and in vitro. J Lipid Res 1998;39:1852-1861.
29. Goldberg IJ: Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996;37:693-707.
30. Connelly PW, Maguire GF, Vezina C, Hegele RA, Kuksis A: Kinetics of very low density lipoproteins by lipoprotein lipase. J Biol Chem 1994;269:20554-20560.
31. Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S: Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chim Acta 1993;216:113-123.
32. Mann WA, Meyer Y, Berg D, Greten H, Beisiegel U: Lipoprotein lipase compensates for the defective function of ApoE variants in vitro by interacting with proteoglycans and lipoprotein receptors. Atherosclerosis 1999;145:61-69.
33. Kobayashi J, Tashiro J, Murano S, Morisaki N, Saito Y: Lipoprotein lipase mass and activity in post-heparin plasma from subjects with intra-abdominal visceral fat accumulation. Clin Endocrinol 1998;48:515-520.
34. Maehira F, Miyagi I, Eguchi Y: Sex- and age-related variations in the in vitro heparin-releasable lipoprotein lipase from mononuclear monocytes in blood. Biochim Biophys Acta 1990;1042:344-351.
35. Huttunen JK, Ehnholm C, Kekki M, Nikkila EA: Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridaemia: Correlations to sex, age and various parameters of triglyceride metabolism. Clin Sci Mol Med 1976;50:249-260.
36. Freeman DJ, Caslake MJ, Griffin BA, Hinnie J, Tan CE, Watson TD, Packard CJ, Shepherd J: The effect of smoking on post-heparin lipoprotein and hepatic lipase, cholesteryl ester transfer protein and lecithin: Cholesterol acyl transferase activities in human plasma. Eur J Clin Invest 1998;28:584-591.